Vyzulta has been approved in Mexico for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, Nicox announced in a press release.
Bausch + Lomb, Nicox’s partner, received the approval for Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) from Mexican authorities.
It has previously been approved in the United States and Canada.
“Vyzulta is now approved in three major markets. This approval will contribute to Nicox revenue stream, and it validates that Nicox is continuing to maximize the value from our partnered assets to complement our own
Uncategorized